Evidence map›Paper›PMID 36645093›Full record

ArticleJournal of the American Heart Association2023

Circulating Progenitor Cells Are Associated With Bioprosthetic Aortic Valve Deterioration: A Preliminary Study.

Yoshihisa Kanaji, Ilke Ozcan, Takumi Toya, Rajiv Gulati, Melissa Young, Tsunekazu Kakuta, Lilach O Lerman, Amir Lerman

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Endothelial Progenitor Cells: Disease Markers and Potential Therapy in Kidney Disease.Journal of the American Society of Nephrology : JASN · 2025
    Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Yoshihisa KanajiDepartment of Cardiovascular Medicine Rochester MN.ORCID 0000-0001-6535-4377
Ilke OzcanDepartment of Cardiovascular Medicine Rochester MN.ORCID 0000-0003-2006-3431
Takumi ToyaDepartment of Cardiovascular Medicine Rochester MN.ORCID 0000-0002-4681-2798
Rajiv GulatiDepartment of Cardiovascular Medicine Rochester MN.ORCID 0000-0002-2713-0433
Melissa YoungDepartment of Cardiovascular Medicine Rochester MN.ORCID 0000-0002-4114-7768
Tsunekazu KakutaDivision of Cardiovascular Medicine Tsuchiura Kyodo General Hospital Ibaraki Japan.ORCID 0000-0002-4004-5292
Lilach O LermanDivision of Nephrology and Hypertension, Mayo Clinic Mayo Clinic Rochester MN.ORCID 0000-0002-3271-3887
Amir LermanDepartment of Cardiovascular Medicine Rochester MN.ORCID 0000-0002-9446-5313
University of Minnesota Rochester · USTsuchiura Kyodo General Hospital · JPMayo Clinic in Arizona · USNational Defense Medical College Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Mechanisms underlying bioprosthetic valve deterioration are multifactorial and incompletely elucidated. Reparative circulating progenitor cells, and conversely calcification-associated osteocalcin expressing circulating progenitor cells, have been linked to native aortic valve deterioration. However, their role in bioprosthetic valve deterioration remains elusive. This study sought to evaluate the contribution of different subpopulations of circulating progenitor cells in bioprosthetic valve deterioration. Methods and Results This single-center prospective study enrolled 121 patients who had peripheral blood mononuclear cells isolated before bioprosthetic aortic valve replacement and had an echocardiographic follow-up ≥2 years after the procedure. Using flow cytometry, fresh peripheral blood mononuclear cells were analyzed for the surface markers CD34, CD133, and osteocalcin. Bioprosthetic valve deterioration was evaluated by hemodynamic valve deterioration (HVD) using echocardiography, which was defined as an elevated mean transprosthetic gradient ≥30 mm Hg or at least moderate intraprosthetic regurgitation. Sixteen patients (13.2%) developed HVD during follow-up for a median of 5.9 years. Patients with HVD showed significantly lower levels of reparative CD34

Indexed as

Aortic Valve StenosisBioprosthesisHeart Valve ProsthesisHeart Valve Prosthesis ImplantationAortic ValveHumansLeukocytes, MononuclearOsteocalcinProspective StudiesProsthesis DesignProsthesis FailureStem CellsTreatment OutcomeOsteocalcinaortic valve stenosisbioprosthetic valve deteriorationcirculating progenitor cellsstructural valve degenerationvalve replacement

Identifiers

PMID36645093
PMCPMC9939063
OpenAlexW4316468782

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.